Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more
Ikena Oncology Inc (IKNA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.030x
Based on the latest financial reports, Ikena Oncology Inc (IKNA) has a cash flow conversion efficiency ratio of -0.030x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.42 Million) by net assets ($115.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ikena Oncology Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ikena Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ikena Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chicago Rivet & Machine Co
NYSE MKT:CVR
|
0.032x |
|
Jasper Mining Corporation
PINK:JAMGF
|
-0.001x |
|
Equatorial Resources Ltd
AU:EQX
|
0.000x |
|
Edesa Biotech Inc
NASDAQ:EDSA
|
-0.142x |
|
Eastern Power Group Public Company Limited
BK:EP
|
0.002x |
|
Darya-Varia Laboratoria Tbk
JK:DVLA
|
0.063x |
|
AUREA SA INH. EO 120
F:94P
|
N/A |
|
North Energy ASA
OL:NORTH
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Ikena Oncology Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Ikena Oncology Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $125.93 Million | $-46.00 Million | -0.365x | +22.23% |
| 2023-12-31 | $169.76 Million | $-79.74 Million | -0.470x | +6.84% |
| 2022-12-31 | $146.97 Million | $-74.11 Million | -0.504x | -73.97% |
| 2021-12-31 | $207.88 Million | $-60.25 Million | -0.290x | -177.43% |
| 2020-12-31 | $-101.05 Million | $-37.83 Million | 0.374x | +148.01% |
| 2019-12-31 | $-61.46 Million | $47.93 Million | -0.780x | -407.93% |
| 2018-12-31 | $-45.84 Million | $-11.61 Million | 0.253x | -- |